{"id":92298,"date":"2024-10-16T14:19:04","date_gmt":"2024-10-16T12:19:04","guid":{"rendered":"https:\/\/www.formycon.com\/?page_id=92298"},"modified":"2026-02-23T08:35:36","modified_gmt":"2026-02-23T07:35:36","slug":"about-formycon","status":"publish","type":"page","link":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/","title":{"rendered":"About Formycon"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;1&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;763255&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; equal_height=&#8221;yes&#8221; gutter_size=&#8221;0&#8243; shift_y=&#8221;0&#8243;][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;2&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_custom_heading text_color=&#8221;color-155072&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;791924&#8243; text_color_type=&#8221;uncode-palette&#8221;]About Formycon[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;114096&#8243; text_color_type=&#8221;uncode-palette&#8221;]Commercial Stage Biosimilar Developer[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;h3&#8243; text_weight=&#8221;300&#8243; text_height=&#8221;fontheight-357766&#8243; uncode_shortcode_id=&#8221;129548&#8243;]Through our biosimilar development projects, Formycon creates not only highly effective, more affordable biologic drugs for patients but also long-term value for its investors. Biosimilars are a new class of medicines\u00a0with a very promising future, and our product candidates are targeted at multi-billion-dollar markets.[\/vc_custom_heading][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;2&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;195133&#8243; row_height_pixel=&#8221;200&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;133257&#8243;][vc_single_image media=&#8221;93864&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;196585&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; back_color=&#8221;color-674378&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;482564&#8243; back_color_type=&#8221;uncode-palette&#8221; row_name=&#8221;EquityStory&#8221;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;190502&#8243; column_width_pixel=&#8221;960&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; shift_y=&#8221;0&#8243;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;3\/12&#8243;][vc_separator sep_color=&#8221;accent&#8221;][vc_empty_space empty_h=&#8221;1&#8243;][vc_column_text uncode_shortcode_id=&#8221;138934&#8243;]<strong>Equity Story<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;9\/12&#8243;][vc_separator sep_color=&#8221;color-100636&#8243;][vc_empty_space empty_h=&#8221;1&#8243;][vc_column_text uncode_shortcode_id=&#8221;702163&#8243;]<strong>Focus on What Matters Most &#8211; Our Biosimilar Platform<\/strong><\/p>\n<p>Formycon is an established, successful, and independent pure-play biosimilar company specializing in the development of cost-effective follow-on products for complex biopharmaceutical medicines. In the rapidly growing biosimilar market, we are committed to expanding and advancing our scalable biosimilar platform. Currently, this platform includes three approved biosimilars for ophthalmology and immunology indications, providing millions of patients worldwide with access to essential and affordable therapies. Additionally, we are developing four next-generation biosimilar candidates, with more to follow.[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;187849&#8243;]<strong>Expertise, Agility, and Flexibility as the Recipe for Success<\/strong><\/p>\n<p>As a pure-play biosimilar company, Formycon holds a distinct competitive advantage. Our focused strategy, agile development processes, and strong partnerships allow us to efficiently develop high-quality follow-on products and quickly adapt to market changes. This flexibility, combined with our high level of scientific expertise, positions us as a reliable and preferred partner in the highly regulated biopharma market. Our goal is to meet the growing global demand for biosimilars and ensure long-term value creation through a diversified portfolio and strong partnerships.[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;595682&#8243;]<strong>Strong Partnerships for Economic Success<\/strong><\/p>\n<p>Strategic partnerships with established manufacturing and commercialization partners are critical to the economic success of our biosimilars. In manufacturing, we select the most suitable partner for each of our biosimilars to ensure a cost-efficient and competitive production process. For global distribution, we form commercialization partnerships with leading pharmaceutical companies such as Fresenius Kabi, Sandoz, and Teva. Thanks to this hybrid business model, we have laid a solid foundation for continuous revenue streams and further growth.[\/vc_column_text][vc_column_text uncode_shortcode_id=&#8221;143385&#8243;]<strong>Participate in Growth with Us as Biosimilar Market Specialists<\/strong><\/p>\n<p>For investors, Formycon\u2019s pure-play approach offers an attractive opportunity to benefit from the dynamic biosimilar market. We develop products that meet the needs of various stakeholders. In addition to patients, doctors, and healthcare systems that directly benefit from the use of biosimilars, pharmaceutical companies also seek our biosimilars to expand their product portfolios in distribution.<\/p>\n<p>With our recent uplisting to the Prime Standard of the Frankfurt Stock Exchange, Formycon has gained significance in the international capital markets. Our solid financial structure and experienced management team provide a reliable foundation for further growth and a strong market position in key global markets.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;2&#8243; bottom_padding=&#8221;3&#8243; back_image=&#8221;93869&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;388087&#8243; row_name=&#8221;CompanyPresentation&#8221;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;268427&#8243; column_width_pixel=&#8221;960&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;4&#8243; shift_y=&#8221;0&#8243;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; style=&#8221;dark&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;3\/12&#8243; uncode_shortcode_id=&#8221;661849&#8243;][vc_empty_space empty_h=&#8221;1&#8243;][vc_column_text text_color=&#8221;color-xsdn&#8221; uncode_shortcode_id=&#8221;781974&#8243; text_color_type=&#8221;uncode-palette&#8221;]<strong><span style=\"color: #ffffff;\">Downloads<\/span><\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;4\/12&#8243;][vc_empty_space empty_h=&#8221;1&#8243;][vc_single_image media=&#8221;97691&#8243; media_width_percent=&#8221;100&#8243; shadow=&#8221;yes&#8221; shadow_weight=&#8221;lg&#8221; uncode_shortcode_id=&#8221;641224&#8243; media_link=&#8221;url:https%3A%2F%2Fwww.formycon.com%2Fwp-content%2Fuploads%2F2026%2F02%2F2025_Formycon-AG-23_02.pdf|target:_blank&#8221;][vc_column_text uncode_shortcode_id=&#8221;189995&#8243;]<a href=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2026\/01\/2025_Formycon-AG-21_01.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #ffffff;\">Company Presentation<\/span><\/a>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;4\/12&#8243;][vc_empty_space empty_h=&#8221;1&#8243;][vc_single_image media=&#8221;92995&#8243; media_width_percent=&#8221;100&#8243; shadow=&#8221;yes&#8221; shadow_weight=&#8221;xl&#8221; uncode_shortcode_id=&#8221;167949&#8243; media_link=&#8221;url:https%3A%2F%2Fwww.formycon.com%2Fwp-content%2Fuploads%2F2025%2F10%2FFactSheet_2025-10_EN.pdf|target:_blank&#8221;][vc_column_text uncode_shortcode_id=&#8221;802226&#8243;]<a href=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/07\/FactSheet_2025-07EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #ffffff;\">Factsheet<\/span><\/a>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row=&#8221;&#8221; row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;4&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;792316&#8243; el_class=&#8221;faq1&#8243; row_name=&#8221;FAQ&#8221; el_id=&#8221;FAQ&#8221;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;3\/12&#8243; uncode_shortcode_id=&#8221;160197&#8243; column_width_pixel=&#8221;960&#8243;][vc_separator sep_color=&#8221;accent&#8221;][vc_empty_space empty_h=&#8221;1&#8243;][vc_column_text uncode_shortcode_id=&#8221;231081&#8243;]<strong>FAQ<\/strong>[\/vc_column_text][\/vc_column][vc_column width=&#8221;9\/12&#8243;][vc_separator sep_color=&#8221;color-100636&#8243;][vc_empty_space empty_h=&#8221;1&#8243;][vc_accordion typography=&#8221;yes&#8221; el_class=&#8221;faqqq&#8221;][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Where will Formycon be in 3 \u2013 5 years?&#8221; tab_id=&#8221;1730790947-1-35&#8243;][vc_column_text uncode_shortcode_id=&#8221;299595&#8243;]In three to five years, we envision Formycon with at least three or four biosimilar products distributed internationally through commercialization partners. Beyond that, our product pipeline will have matured further and expanded. The company will have established itself as a globally renowned player in biosimilars, grounded in solid financials.[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;What is the difference between biosimilars and generics?&#8221; tab_id=&#8221;1730790947-2-50&#8243;][vc_column_text uncode_shortcode_id=&#8221;313186&#8243;]Unlike generics, which are chemically synthesized and contain the exact same active ingredient as the originally patented drug, biosimilars are produced using living organisms. This is usually done in cell cultures, such as bacteria, yeast cells, or mammalian cells<sup>1<\/sup>. This is why biosimilar development takes between 7 to 10 years<sup>2<\/sup> (compared to 2 to 3 years for generics<sup>3<\/sup>) and requires a budget of between 150 to 300 million euros<sup>3<\/sup> (compared to 5 to 10 million euros for a generic<sup>3<\/sup>).[\/vc_column_text][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;135702&#8243; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;111878&#8243;]Sources:<br \/>\n<sup>1 <\/sup><a href=\"https:\/\/probiosimilars.de\/topics\/the-importance-of-biosimilars\/what-are-biosimilars\/?lang=en\" target=\"_blank\" rel=\"noopener\">What are biosimilars?<\/a><br \/>\n<sup>2 <\/sup>IQVIA Assessing the Biosimilar Void.<br \/>\n<sup>3 <\/sup>Company estimates; development times and costs vary greatly<br \/>\ndepending on the indication and type of active ingredient.[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;When will new biosimilar candidates be added to the pipeline?&#8221; tab_id=&#8221;1730916296154-2-10&#8243;][vc_column_text uncode_shortcode_id=&#8221;182852&#8243;]Our most valuable assets are our pipeline projects, as they create value. Therefore, our focus will remain on expanding our platform. Currently, we plan to launch a new biosimilar candidate every 12 to 18 months.[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Will you stick to the current therapeutic areas, or are other areas being considered?&#8221; tab_id=&#8221;1730916406076-3-1&#8243;][vc_column_text uncode_shortcode_id=&#8221;110893&#8243;]We evaluate candidates independently of their therapeutic area. In our view, the key to a sustainable and value-generating platform is a smart mix of niche and blockbuster products in selecting the right candidates.[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;How likely is it for a biosimilar to gain approval?&#8221; tab_id=&#8221;1730916439683-4-4&#8243;][vc_column_text uncode_shortcode_id=&#8221;348657&#8243;]The likelihood of a biosimilar receiving approval is around 95%, provided that development has been conducted with precision and care throughout. The decisive inflection point is known as the &#8220;Technical Proof of Similarity&#8221; (TPOS). From this stage onward, the probability of successful approval increases with each phase.[\/vc_column_text][vc_single_image media=&#8221;93824&#8243; media_width_percent=&#8221;100&#8243; uncode_shortcode_id=&#8221;529139&#8243;][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;617223&#8243; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;145201&#8243;]Source: &#8220;The Path Towards a Tailored Clinical Biosimilar Development,&#8221; Schiestl et al., 2020[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;What role does AI currently play in biosimilar development?&#8221; tab_id=&#8221;1730916597047-5-4&#8243;][vc_column_text uncode_shortcode_id=&#8221;199045&#8243;]Formycon uses AI tools to speed up and streamline internal processes. AI can also be used in product development, particularly for the efficient selection of excipients in formulation development and for optimizing formulation stability. Additionally, we use AI to generate better forecasts from our data. In the future, AI will undoubtedly play an even larger role in diagnostics, both within clinical trials and in clinical practice.[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;How does Formycon differentiate itself from competitors, especially large pharmaceutical companies?&#8221; tab_id=&#8221;1730916633924-6-2&#8243;][vc_column_text uncode_shortcode_id=&#8221;170190&#8243;]Compared to large pharmaceutical companies, we are able to operate like an agile speedboat, adapting quickly and flexibly to current conditions. In the biosimilar field, it\u2019s unique that competitors can also be potential partners. What sets Formycon apart are our experts exclusively focused on biosimilars, with many years of experience in the development and approval of biosimilars, and who thoroughly understand all opportunities and challenges across the value chain. Furthermore, there are over 200 biological active ingredients, and no company, not even large pharmaceutical companies, can develop all of them independently. This makes us an attractive partner for them as well.[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Why are biosimilars important for global healthcare systems?&#8221; tab_id=&#8221;1730916664899-7-5&#8243;][vc_column_text uncode_shortcode_id=&#8221;202572&#8243;]The development of this class of drugs clearly points to further uptake and establishment of biosimilars. This is evidenced by the cost savings that biosimilars have achieved in recent years. IQVIA&#8217;s Global Use of Medicines report projects that biosimilars will generate global savings of $290 billion by 2027. These savings provide healthcare systems with more financial flexibility in other areas, making biosimilars an essential contribution to sustainable healthcare.[\/vc_column_text][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;145589&#8243; el_width=&#8221;60%&#8221; el_height=&#8221;1px&#8221;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;619642&#8243;]Source: <a href=\"https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/the-global-use-of-medicines-2023\" target=\"_blank\" rel=\"noopener\">IQVIA \u2013 The global use of Medicines 2023<\/a>[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Which pharmaceutical partners are you currently working with on your biosimilar projects?&#8221; tab_id=&#8221;1730916814145-8-4&#8243;][vc_column_text uncode_shortcode_id=&#8221;166274&#8243;]<\/p>\n<p data-start=\"155\" data-end=\"530\"><strong data-start=\"155\" data-end=\"165\">FYB201<\/strong> is marketed under the brand name <strong data-start=\"199\" data-end=\"211\">Ongavia\u00ae<\/strong> in the United Kingdom, <strong data-start=\"235\" data-end=\"247\">Ranopto\u00ae<\/strong> in Canada, and <strong data-start=\"263\" data-end=\"277\">Ranivisio\u00ae<\/strong> in Europe and additional countries by <strong data-start=\"316\" data-end=\"345\">Teva Pharmaceuticals Ltd.<\/strong> In the United States, it is commercialized as <strong data-start=\"392\" data-end=\"404\">Cimerli\u00ae<\/strong> by <strong data-start=\"408\" data-end=\"418\" data-is-only-node=\"\">Sandoz<\/strong>, while in the MENA region it is marketed by <strong data-start=\"463\" data-end=\"476\">MS Pharma<\/strong> under the brand names <strong data-start=\"499\" data-end=\"510\">Uptera\u00ae<\/strong> and <strong data-start=\"515\" data-end=\"527\">Ravegza\u00ae<\/strong>.<\/p>\n<p data-start=\"532\" data-end=\"771\">For <strong data-start=\"536\" data-end=\"554\">FYB202\/Otulfi\u00ae<\/strong>, <strong data-start=\"556\" data-end=\"574\">Fresenius Kabi<\/strong> is our commercialization partner for the key global markets. In Germany, FYB202 is additionally distributed by <strong data-start=\"686\" data-end=\"710\">Teva Pharmaceuticals<\/strong> as additional commercialization partner under the brand name <strong data-start=\"756\" data-end=\"768\">Fymskina<\/strong>.<\/p>\n<p data-start=\"773\" data-end=\"1367\"><strong data-start=\"773\" data-end=\"783\">FYB203<\/strong> will be marketed under the brand name <strong data-start=\"822\" data-end=\"836\">AHZANTIVE\u00ae<\/strong> in the United States and Canada by <strong data-start=\"872\" data-end=\"897\">Valorum Biologics LLC<\/strong>. Under the same brand name, FYB203 will be commercialized in the Asia-Pacific region by <strong data-start=\"986\" data-end=\"1010\">Lotus Pharmaceutical<\/strong>, and in large parts of Europe as well as in Israel by our strategic commercialization partner <strong data-start=\"1105\" data-end=\"1134\">Teva Pharmaceuticals Ltd.<\/strong> As a additional commercialization partner, <strong data-start=\"1162\" data-end=\"1178\">Horus Pharma<\/strong> will distribute FYB203 in selected European countries under the brand name <strong data-start=\"1254\" data-end=\"1265\" data-is-only-node=\"\">Baiama\u00ae<\/strong>. In the MENA region, <strong data-start=\"1287\" data-end=\"1300\">MS Pharma<\/strong> will commercialize the product under the brand name <strong data-start=\"1353\" data-end=\"1364\">Fovlya\u00ae<\/strong>.<\/p>\n<p>For FYB206 and other biosimilar candidates, no commercialization partnerships have been announced yet.[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Is the integration of different segments along the value chain conceivable?&#8221; tab_id=&#8221;1730916881235-9-0&#8243;][vc_column_text uncode_shortcode_id=&#8221;150096&#8243;]We see ourselves as an R&amp;D powerhouse with a fully scalable biosimilar development platform and are very comfortable in this role. However, Formycon is growth-oriented and aims to establish itself as a global player in biosimilars. This fundamentally includes evaluating opportunities for inorganic growth along the value chain.[\/vc_column_text][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Is a dividend planned?&#8221; tab_id=&#8221;1730916911268-10-6&#8243;][vc_column_text uncode_shortcode_id=&#8221;425979&#8243;]Formycon is a growth-oriented company with currently only one product on the market. Therefore, to support sustainable and value-generating company development, we are likely to reinvest returns into existing and new development projects, and we do not currently plan to pay a dividend.[\/vc_column_text][\/vc_accordion_tab][\/vc_accordion][vc_empty_space empty_h=&#8221;3&#8243;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;1&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;763255&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; [&hellip;]<\/p>\n","protected":false},"author":23,"featured_media":93092,"parent":78112,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-92298","page","type-page","status-publish","has-post-thumbnail","hentry","page_category-ir-update-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>About Formycon - Formycon AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"About Formycon - Formycon AG\" \/>\n<meta property=\"og:description\" content=\"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;1&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;763255&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/\" \/>\n<meta property=\"og:site_name\" content=\"Formycon AG\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T07:35:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2024\/10\/Header_About-Formycon.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/\",\"url\":\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/\",\"name\":\"About Formycon - Formycon AG\",\"isPartOf\":{\"@id\":\"https:\/\/www.formycon.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2024\/10\/Header_About-Formycon.png\",\"datePublished\":\"2024-10-16T12:19:04+00:00\",\"dateModified\":\"2026-02-23T07:35:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#primaryimage\",\"url\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2024\/10\/Header_About-Formycon.png\",\"contentUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2024\/10\/Header_About-Formycon.png\",\"width\":1600,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.formycon.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors\",\"item\":\"https:\/\/www.formycon.com\/en\/investor-relations\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"About Formycon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.formycon.com\/en\/#website\",\"url\":\"https:\/\/www.formycon.com\/en\/\",\"name\":\"Formycon AG\",\"description\":\"Global Quality Biosimilars\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.formycon.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"About Formycon - Formycon AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/","og_locale":"en_US","og_type":"article","og_title":"About Formycon - Formycon AG","og_description":"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;1&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;763255&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; [&hellip;]","og_url":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/","og_site_name":"Formycon AG","article_modified_time":"2026-02-23T07:35:36+00:00","og_image":[{"width":1600,"height":600,"url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2024\/10\/Header_About-Formycon.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/","url":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/","name":"About Formycon - Formycon AG","isPartOf":{"@id":"https:\/\/www.formycon.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#primaryimage"},"image":{"@id":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#primaryimage"},"thumbnailUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2024\/10\/Header_About-Formycon.png","datePublished":"2024-10-16T12:19:04+00:00","dateModified":"2026-02-23T07:35:36+00:00","breadcrumb":{"@id":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#primaryimage","url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2024\/10\/Header_About-Formycon.png","contentUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2024\/10\/Header_About-Formycon.png","width":1600,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.formycon.com\/en\/investor-relations\/about-formycon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.formycon.com\/en\/"},{"@type":"ListItem","position":2,"name":"Investors","item":"https:\/\/www.formycon.com\/en\/investor-relations\/"},{"@type":"ListItem","position":3,"name":"About Formycon"}]},{"@type":"WebSite","@id":"https:\/\/www.formycon.com\/en\/#website","url":"https:\/\/www.formycon.com\/en\/","name":"Formycon AG","description":"Global Quality Biosimilars","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.formycon.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-13 09:45:14","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/92298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/comments?post=92298"}],"version-history":[{"count":8,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/92298\/revisions"}],"predecessor-version":[{"id":99216,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/92298\/revisions\/99216"}],"up":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78112"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media\/93092"}],"wp:attachment":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media?parent=92298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}